These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

603 related articles for article (PubMed ID: 19249675)

  • 1. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited.
    Loges S; Mazzone M; Hohensinner P; Carmeliet P
    Cancer Cell; 2009 Mar; 15(3):167-70. PubMed ID: 19249675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
    Shojaei F; Ferrara N
    Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of resistance to antiangiogenesis therapy.
    Azam F; Mehta S; Harris AL
    Eur J Cancer; 2010 May; 46(8):1323-32. PubMed ID: 20236818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy.
    van der Meel R; Symons MH; Kudernatsch R; Kok RJ; Schiffelers RM; Storm G; Gallagher WM; Byrne AT
    Drug Discov Today; 2011 Mar; 16(5-6):219-28. PubMed ID: 21262381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy.
    Glade Bender J; Cooney EM; Kandel JJ; Yamashiro DJ
    Drug Resist Updat; 2004; 7(4-5):289-300. PubMed ID: 15533766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage.
    Koh YJ; Kim HZ; Hwang SI; Lee JE; Oh N; Jung K; Kim M; Kim KE; Kim H; Lim NK; Jeon CJ; Lee GM; Jeon BH; Nam DH; Sung HK; Nagy A; Yoo OJ; Koh GY
    Cancer Cell; 2010 Aug; 18(2):171-84. PubMed ID: 20708158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelets and cancer: implications for antiangiogenic therapy.
    Trikha M; Nakada MT
    Semin Thromb Hemost; 2002 Feb; 28(1):39-44. PubMed ID: 11885024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chapter 6. Mouse models to investigate anti-cancer effects of VEGF inhibitors.
    Crawford Y; Ferrara N
    Methods Enzymol; 2008; 445():125-39. PubMed ID: 19022058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy.
    Ellis LM; Hicklin DJ
    Clin Cancer Res; 2008 Oct; 14(20):6371-5. PubMed ID: 18927275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic.
    Epstein RJ
    Cancer Metastasis Rev; 2007 Dec; 26(3-4):443-52. PubMed ID: 17786538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiangiogenic cancer therapy.
    Cao Y
    Semin Cancer Biol; 2004 Apr; 14(2):139-45. PubMed ID: 15018898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VEGF inhibition: insights from preclinical and clinical studies.
    Crawford Y; Ferrara N
    Cell Tissue Res; 2009 Jan; 335(1):261-9. PubMed ID: 18766380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel angiogenesis inhibitors: addressing the issue of redundancy in the angiogenic signaling pathway.
    Ribatti D
    Cancer Treat Rev; 2011 Aug; 37(5):344-52. PubMed ID: 21435792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why do tumors become resistant to antiangiogenesis drugs?
    Schmidt C
    J Natl Cancer Inst; 2009 Nov; 101(22):1530-2. PubMed ID: 19880813
    [No Abstract]   [Full Text] [Related]  

  • 15. Persistent vascular normalization as an alternative goal of anti-angiogenic cancer therapy.
    Sato Y
    Cancer Sci; 2011 Jul; 102(7):1253-6. PubMed ID: 21401807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Role of angiogenesis in the growth and progression of tumors. Treatment with angiogenesis inhibitors: from promising results in experimental animal models to the reality of clinical use].
    Plavetić ND; Letilović T; Vrbanec D
    Lijec Vjesn; 2003; 125(9-10):260-5. PubMed ID: 15038217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of angiogenesis and the angiogenesis/invasion shift.
    Bikfalvi A; Moenner M; Javerzat S; North S; Hagedorn M
    Biochem Soc Trans; 2011 Dec; 39(6):1560-4. PubMed ID: 22103487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanisms and therapeutic development of angiogenesis inhibitors.
    Cao Y
    Adv Cancer Res; 2008; 100():113-31. PubMed ID: 18620094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor.
    Shibuya M
    FEBS J; 2009 Sep; 276(17):4636-43. PubMed ID: 19664071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor angiogenesis in melanoma.
    Marneros AG
    Hematol Oncol Clin North Am; 2009 Jun; 23(3):431-46, vii-viii. PubMed ID: 19464595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.